

Quality-Data Code Submission Error Report by Measure

Report Includes Data from the July through November 2007 TAP Files Only

Measure	Reporting Opportunities	QDC Occurrences			QDC Exceptions								
		# Reported ^a	# Accepted ^b	% Accepted	Denominator Mismatches						NPI Problem		
					Gender		Age		Total Denom Mismatch ^c		QDC No NPI		
					#	%	#	%	#	%	#	%	
Advance Care													
#47 Advance Care Plan	55,136,995	462,731	357,170	77.19%	0	0.00%	31,844	6.88%	105,561	22.81%	97,516	21.07%	
Asthma													
#53 Pharmacologic Therapy	17,966	5,669	142	2.50%	0	0.00%	5,426	95.71%	5,527	97.50%	895	15.79%	
#64 Asthma Assessment	17,966	1,958	89	4.55%	0	0.00%	1,833	93.62%	1,869	95.45%	365	18.64%	
Breast Cancer													
#71 Hormonal Therapy for Stage IC-III, ER/PR Positive Breast Ca	522,100	58,890	50,924	86.47%	206	0.35%	0	0.00%	7,966	13.53%	8,922	15.15%	
CABG													
#43 Use of IMA in CABG Surgery	41,565	15,392	10,175	66.11%	0	0.00%	0	0.00%	5,217	33.89%	1,213	7.88%	
#44 Pre-Operative Beta-Blocker in Isolated CABG Surgery	41,565	10,425	6,719	64.45%	0	0.00%	0	0.00%	3,706	35.55%	884	8.48%	
Cataracts													
#15 Assessment of Visual Functional Status	2,310,522	590,933	459,120	77.69%	0	0.00%	21	0.00%	131,813	22.31%	93,129	15.76%	
#16 Doc of Pre-Surgical Axial Length, Corneal Power Measurement and Method of Intraocular Lens Power Calculation	1,142,351	228,941	181,650	79.34%	0	0.00%	4	0.00%	47,291	20.66%	34,657	15.14%	
#17 Pre-Surgical Dilated Fundus Evaluation	1,146,710	220,481	170,032	77.12%	0	0.00%	3	0.00%	50,449	22.88%	33,630	15.25%	
Chemotherapy													
#73 Plan Documented Before Chemotherapy Administered	189,927	58,437	16,678	28.54%	0	0.00%	0	0.00%	41,759	71.46%	3,438	5.88%	
Chest Pain													
#54 ECG Performed for Non-Traumatic Chest Pain	482,886	387,760	244,636	63.09%	0	0.00%	5,023	1.30%	143,124	36.91%	50,162	12.94%	
Colon Cancer													
#72 Chemotherapy for Stage III	119,344	14,785	8,790	59.45%	0	0.00%	3,224	21.81%	5,995	40.55%	1,499	10.14%	
Chronic Obstructive Pulmonary Disease (COPD)													
#51 Spirometry	1,137,936	53,296	37,679	70.70%	0	0.00%	1	0.00%	15,617	29.30%	7,648	14.35%	
#52 Bronchodilator Therapy	1,137,936	52,842	32,391	61.30%	0	0.00%	2	0.00%	20,451	38.70%	6,589	12.47%	
Coronary Artery Disease													
#6 Oral Antiplatelet Therapy Prescribed for Patients with CAD	3,100,482	585,946	429,454	73.29%	0	0.00%	6	0.00%	156,492	26.71%	37,462	6.39%	
#7 Beta-Blocker Therapy for CAD Patients with Prior MI	111,452	256,848	28,873	11.24%	0	0.00%	5	0.00%	227,975	88.76%	11,089	4.32%	
Depression													
#9 Antidepressant Meds During Acute Phase for Patients with New Episode of Major Depression	819,053	7,255	3,676	50.67%	0	0.00%	1	0.01%	3,579	49.33%	965	13.30%	
Diabetes													
#1 Hemoglobin A1c - Poor Control	2,580,099	403,763	195,960	48.53%	0	0.00%	125,404	31.06%	207,803	51.47%	42,275	10.47%	

Measure	Reporting Opportunities	QDC Occurrences			QDC Exceptions							
		# Reported ^a	# Accepted ^b	% Accepted	Denominator Mismatches						NPI Problem	
					Gender		Age		Total Denom Mismatch ^c		QDC No NPI	
					#	%	#	%	#	%	#	%
#2 LDL Control	2,580,099	383,279	185,818	48.48%	0	0.00%	118,454	30.91%	197,461	51.52%	39,902	10.41%
#3 High Blood Pressure Control	2,580,099	619,166	191,602	30.95%	0	0.00%	248,247	40.09%	427,564	69.05%	60,444	9.76%
ESRD												
#37 Dialysis Dose	470,967	65,642	55,381	84.37%	0	0.00%	15	0.02%	10,261	15.63%	3,784	5.76%
#38 Hematocrit Level	470,967	67,620	57,123	84.48%	0	0.00%	15	0.02%	10,497	15.52%	3,607	5.33%
Fall Risk												
#4 Screening for Future Fall Risk	45,642,137	331,732	243,722	73.47%	0	0.00%	20,854	6.29%	88,010	26.53%	85,969	25.92%
GERD												
#60 Assessment for Alarm Symptoms	604,534	34,929	20,046	57.39%	0	0.00%	0	0.00%	14,883	42.61%	5,106	14.62%
#61 Upper Endoscopy for Patients with Alarm Symptoms	604,534	37,993	20,275	53.37%	0	0.00%	0	0.00%	17,718	46.63%	5,621	14.79%
#62 Biopsy for Barrett's Esophagus	133,941	11,723	5,919	50.49%	0	0.00%	0	0.00%	5,804	49.51%	2,215	18.89%
#63 Barium Swallow - Inappropriate Use	604,534	16,798	11,034	65.69%	0	0.00%	0	0.00%	5,764	34.31%	3,377	20.10%
Primary Open Angle Glaucoma												
#12 Optic Nerve Evaluation	1,733,484	520,008	409,338	78.72%	0	0.00%	10	0.00%	110,670	21.28%	97,403	18.73%
Heart Failure												
#5 ACE Inhibitor or ARB Therapy for LVSD	956,055	214,748	81,111	37.77%	0	0.00%	8	0.00%	133,637	62.23%	13,429	6.25%
#8 Beta-Blocker Therapy for LVSD	845,454	362,437	77,331	21.34%	0	0.00%	9	0.00%	285,106	78.66%	18,786	5.18%
Imaging Stroke												
#10 CT or MRI Reports	247,091	62,110	40,002	64.41%	0	0.00%	1	0.00%	22,108	35.59%	3,826	6.16%
#11 Carotid Imaging Reports	144,145	18,948	12,209	64.43%	0	0.00%	3	0.02%	6,739	35.57%	1,471	7.76%
Chronic Lymphocytic Leukemia (CLL)												
#70 Baseline Flow Cytometry	58,265	7,828	6,206	79.28%	0	0.00%	0	0.00%	1,622	20.72%	1,063	13.58%
Macular Degeneration												
#13 Age-Related Eye Disease Study (AREDS) Prescribed/Recommended	959,309	284,996	221,879	77.85%	0	0.00%	239	0.08%	63,117	22.15%	59,683	20.94%
#14 Dilated Macular Examination	959,309	319,131	248,810	77.96%	0	0.00%	331	0.10%	70,321	22.04%	61,481	19.27%
Myelodysplastic Syndrome (MDS) and Acute Leukemias												
#67 Baseline Cytogenetic Testing Performed on Bone Marrow	67,092	9,734	6,867	70.55%	0	0.00%	0	0.00%	2,867	29.45%	1,125	11.56%
#68 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	58,138	9,778	5,809	59.41%	0	0.00%	0	0.00%	3,969	40.59%	937	9.58%
Medication Reconciliation												
#46 Medication Reconciliation	3,941,034	32,673	6,961	21.31%	0	0.00%	2,270	6.95%	25,712	78.69%	3,918	11.99%
Melanoma												
#25 Patient Medical History	91,781	27,752	19,682	70.92%	0	0.00%	0	0.00%	8,070	29.08%	4,323	15.58%
#26 Complete Physical Skin Examination	91,781	27,665	19,422	70.20%	0	0.00%	0	0.00%	8,243	29.80%	4,370	15.80%
#27 Counseling on Self-Examination	91,781	26,717	18,703	70.00%	0	0.00%	1	0.00%	8,014	30.00%	4,346	16.27%
Multiple Myeloma												
#69 Treatment with Bisphosphonates	48,948	7,217	5,507	76.31%	0	0.00%	0	0.00%	1,710	23.69%	944	13.08%
Myocardial Infarction												

Measure	Reporting Opportunities	QDC Occurrences			QDC Exceptions							
		# Reported ^a	# Accepted ^b	% Accepted	Denominator Mismatches						NPI Problem	
					Gender		Age		Total Denom Mismatch ^c		QDC No NPI	
					#	%	#	%	#	%	#	%
#28 Aspirin at Arrival	34,863	12,198	9,163	75.12%	0	0.00%	0	0.00%	3,035	24.88%	1,277	10.47%
#29 Beta-Blocker at Time of Arrival	38,674	4,148	2,220	53.52%	0	0.00%	0	0.00%	1,928	46.48%	406	9.79%
Osteoporosis												
#24 Osteoporosis: Communication with the Physician Managing Ongoing Care Post Fracture	259,024	5,458	1,948	35.69%	0	0.00%	40	0.73%	3,510	64.31%	398	7.29%
#39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	25,010,641	264,568	167,246	63.21%	13,498	5.10%	11,547	4.36%	97,322	36.79%	84,298	31.86%
#40 Osteoporosis: Management Following Fracture	259,024	369,797	1,519	0.41%	0	0.00%	1,592	0.43%	368,278	99.59%	29,037	7.85%
#41 Osteoporosis: Pharmacologic Therapy	366,289	102,861	31,271	30.40%	0	0.00%	634	0.62%	71,590	69.60%	10,016	9.74%
#42 Counseling for Vitamin D, Calcium Intake, and Exercise	370,398	74,629	24,945	33.43%	0	0.00%	1	0.00%	49,684	66.57%	8,476	11.36%
Perioperative Care												
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	1,125,274	914,108	70,134	7.67%	0	0.00%	111	0.01%	843,974	92.33%	54,994	6.02%
#21 Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	875,283	65,666	49,501	75.38%	0	0.00%	8	0.01%	16,165	24.62%	9,289	14.15%
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	933,997	72,732	38,927	53.52%	0	0.00%	6	0.01%	33,805	46.48%	10,172	13.99%
#23 VTE Prophylaxis	740,842	46,848	32,417	69.20%	0	0.00%	10	0.02%	14,431	30.80%	6,236	13.31%
#30 Timing of Prophylactic Antibiotic - Administering Physician	412,730	458,109	360,863	78.77%	0	0.00%	54	0.01%	97,246	21.23%	24,106	5.26%
#45 Discontinuation of Prophylactic Antibiotics	144,247	63,028	26,186	41.55%	0	0.00%	3	0.00%	36,842	58.45%	4,690	7.44%
Pharyngitis												
#66 Appropriate Testing for Children Pneumonia	22	19	0	0.00%	0	0.00%	18	94.74%	19	100.00%	2	10.53%
#56 Vital Signs for Community-Acquired Bacterial Pneumonia	337,257	78,737	59,761	75.90%	0	0.00%	1	0.00%	18,976	24.10%	6,497	8.25%
#57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	337,257	105,707	76,553	72.42%	0	0.00%	1	0.00%	29,154	27.58%	11,116	10.52%
#58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia	337,257	73,575	53,175	72.27%	0	0.00%	1	0.00%	20,400	27.73%	10,298	14.00%
#59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	337,257	56,867	43,939	77.27%	0	0.00%	1	0.00%	12,928	22.73%	5,088	8.95%
Radiation Therapy (RT)												
#74 RT Recommended for Invasive Breast Ca Patients with Breast Conserving Surgery	19,958	6,212	892	14.36%	88	1.42%	3,267	52.59%	5,320	85.64%	510	8.21%
Retinopathy												

Measure	Reporting Opportunities	QDC Occurrences			QDC Exceptions							
		# Reported ^a	# Accepted ^b	% Accepted	Denominator Mismatches						NPI Problem	
					Gender		Age		Total Denom Mismatch ^c		QDC No NPI	
					#	%	#	%	#	%	#	%
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	280,147	142,554	79,440	55.73%	0	0.00%	0	0.00%	63,114	44.27%	25,031	17.56%
#19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	280,147	194,364	84,644	43.55%	0	0.00%	1	0.00%	109,720	56.45%	32,405	16.67%
Stroke and Stroke Rehabilitation												
#31 DVT Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	99,431	4,190	2,236	53.37%	0	0.00%	0	0.00%	1,954	46.63%	262	6.25%
#32 Discharged on Antiplatelet Therapy	119,751	5,294	3,046	57.54%	0	0.00%	0	0.00%	2,248	42.46%	643	12.15%
#33 Anticoagulant Therapy Prescribed for Afib at Discharge	411	1,687	38	2.25%	0	0.00%	0	0.00%	1,649	97.75%	83	4.92%
#34 t-PA Considered	81,723	3,818	1,759	46.07%	0	0.00%	0	0.00%	2,059	53.93%	328	8.59%
#35 Screening for Dysphagia	83,511	3,580	1,784	49.83%	0	0.00%	0	0.00%	1,796	50.17%	229	6.40%
#36 Consideration of Rehabilitation Services	80,796	4,067	2,073	50.97%	0	0.00%	0	0.00%	1,994	49.03%	247	6.07%
Syncope												
#55 ECG Performed for Syncope	139,922	388,026	72,321	18.64%	0	0.00%	62,953	16.22%	315,705	81.36%	44,932	11.58%
Upper Respiratory Infection												
#65 Appropriate Treatment for Children	27	11	1	9.09%	0	0.00%	10	90.91%	10	90.91%	2	18.18%
Urinary Incontinence												
#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older	25,010,641	91,818	59,521	64.82%	3,344	3.64%	3,061	3.33%	32,297	35.18%	33,607	36.60%
#49 Characterization of UI in Women Aged 65 Years and Older	174,540	28,207	12,688	44.98%	392	1.39%	808	2.86%	15,519	55.02%	2,935	10.41%
#50 Plan of Care for UI in Women Aged 65 Years and Older	174,540	26,896	12,370	45.99%	344	1.28%	764	2.84%	14,526	54.01%	2,753	10.24%

^a An occurrence of a Quality-Data Code (QDC) on a claim – not necessarily a valid or appropriate use of Quality-Data Code.

^b Quality-Data Code Accepted = a valid PQRI code, used appropriately for a measure.

^c Total # of diagnosis or procedure errors including denominator mismatches for gender and age.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recently received pilot participant list from ORD).